• Radiation Oncology Journal
• /
• v.4 no.2
• /
• pp.135-139
• /
• 1986

Seven patients having midline granuloma received local irradiation from March 1983 to June 1986. Clinically, all of the 7 patients had pansinusitis with necrotic destruction of the involved sites and one case revealed colonic lesion. Each of the patients received a tumor dose of $4,000\~5,000 cGy/5\~6$ wks to the upper aerodigestive tract using a 6-MV linear accelerator. Complete and partial remission occured in 3 patients each, and in one case, the disease progressed despite of the irradiation.

• Radiation Oncology Journal
• /
• v.3 no.1
• /
• pp.59-64
• /
• 1985

Computation of three dimensional dose distribution using CT image and RT plan was applied to a case of pituitary adenoma. Algorithm was based on two dimensional Tissue Maximun Ratio model extended to the third dimension. The resulting isodose curve of transeverse, coronal and sagittal section was demonstrated. This RT plan allows computation of dose distribution in any arbitarily defined plane in addition to conventional cross sectional view.

• Korean Journal of Head & Neck Oncology
• /
• v.6 no.1
• /
• pp.40-45
• /
• 1990

Thirty five lesions of 35 patients with locally advanced malignant tumors of head and neck were received thermoradiotherapy with ultrasound and/or 915 MHz microwave. Most of all patients were failed with previous conventional therapeutic trial. Hyperthermia had been done immediately after radiotherapy, twice a week, $43^{\circ}C$ for one hour and radiotherapy had been done 5 fractions per week with a fraction size of 2 Gy up to total 30 to 60 Gy. Conclusions are as follows; 1) Total response rate (CR+PR) of thermoradiotherapy with microwave and ultrasound was 80%. 2) Tumor depth, minimum temperature of tumor center, number of heat fraction and irradiation dose were statistically significant factors affecting response. 3) Hyperthermia with microwave and ultrasound can be used efficiently to control locally advanced malignant tumors in head and neck whether previously received near tolerance dose of radiotherapy or not.

• Radiation Oncology Journal
• /
• v.13 no.1
• /
• pp.63-67
• /
• 1995

A retrospective study was carried out of 20 patients with histologically proven invasive carcinoma of the vagina from 1979 to 1993; 17 cases with curative primary radiotherapy and three cases with postoperative radiotherapy. The five and ten year overall survival rates were $79\%$ and $53\%$, respectively. Survival was strongly correlated with stage. Five year survival rates of stage I, stage II, and stage III, IV were $100\%$, $78\%$, and $0\%$, respectively. Eight patients experienced recurrences: five within the irradiated volume, two distant metastasis, and one combined both local and distant metastasis. There was no significant late complication. From these data, radiation is effective in the management of the vaginal cancer patients and optimum treatment modality and total dose recommendation are made.

• Radiation Oncology Journal
• /
• v.6 no.1
• /
• pp.75-80
• /
• 1988

Twenty seven lesions of 25 patients with locally advanced malignant tumors were treated with combined hyperthermia introduced by microwave and ultrasound and radiotherapy. Most of all patients were failed with previous conventional therapeutic trial. Hyperthermia had been done immediately after radiotherapy, twice a week, $43^{\circ}C$ for one hour and radiotherapy had been done 5 fractions per week with fraction size of 2Gy upto 30 to 60Gy. Conclusions are as follows. 1. Total response rate (PR+PR) to thermoradiotherapy with microwave and ultrasound was $81\%$. 2. Tumor depth, minimum temperature of tumor center, number of heat fraction and radiation dose were statistically significant factors affecting response. 3. Hyperthermia with microwave and ultrasound can be used efficiently to control locally advanced malignant disease whether previously received near tolerance dose of radiotherapy or not.

• Korean Journal of Head & Neck Oncology
• /
• v.16 no.1
• /
• pp.9-13
• /
• 2000

Objectives: To determine the tumor interstitial fluid pressure(TIFP) in patients with head and neck cancerand predict radiotherapy outcome.Materials and Methods: In 12 biopsy proven primary head and neck cancer patients with accessible by direct inspection and palpation, and of sufficient thickness(>1cm) to permit accurate needle placement, we measured TIFP at cervical lymph node before and during radiotherapy using a modified wick-in-needle technique. Tumor size was measured clinically and radiologically. Results: The mean preradiotherapy TIFP was 23.4mmHg. Preradiotherapy TIFP had significant relationship with tumor size(p=0.0009). Preradiotherapy TIFP was not different between complete response group and partial or less response group(p=0.114). Radiotherapy outcome was not different between group with above and group with below average TIFP(p=0.09). Conclusion: The mean TIFP was elevated with 23.4mmHg before radiation therapy. Preradiotherapy TIFP had significant relationship with tumor size. It is not definitive that TIFP could be prognostic indicator of radiation response.

• Radiation Oncology Journal
• /
• v.10 no.1
• /
• pp.121-123
• /
• 1992

New measurement method for $S_{p}$ factors (Phantom Scatter Factors) is presented. The theoretical development of the approach is disscused showing that $S_{p}$ factors can be obtained from three measurements of ionnization in a blocked, reference field and open field. This method has been tested using $^{60}Co$ gamma rays. The results were within 1% deviation between the theory and the experiment for the $S_{p}$ factor. The new method does not need air measurement, and we could could determine the $S_P$ factors with a small piece of block

• Radiation Oncology Journal
• /
• v.7 no.2
• /
• pp.185-188
• /
• 1989

Radiation treatment results were analyzed in a retrospective analysis of 47 patients with pituitary adenoma treated with radiation alone or combined with surgery from 1974 through 1987 at the Department of Therapeutic Radiology of Kyung Hee University. The 5-year overall survival rates for all patients was $80.4\%$ Radiation therapy was effective for improving visual symptoms and headache, but could not normalize amenorrhea and galactorrhea. There was no difference of survival rate between radiation alone and combination with surgery. Prognostic factors such as age, sex, disease type, visual field, headache and surgical treatment were statistically no significant in survival rates of these patients.

• Radiation Oncology Journal
• /
• v.7 no.2
• /
• pp.287-291
• /
• 1989

Radiation dosimetry has been extended to small fields less than $4\times4cm^2$ which may be suitable for irradiation of small intracranial tumors. Special consideration was given to the percentage depth dose and scatter correction factors with 0.14ml ion chamber, film dosimetry and TLD measurement. Calculated dose distributions were compared with measured data.

• Radiation Oncology Journal
• /
• v.11 no.1
• /
• pp.127-132
• /
• 1993

Total of 53 patients of unresectable and recurrent rectal cancer treated with neutron beam during the period from Oct.1987 to Apr.1992 were analyzed. Dose fractionation for the neutron only group was 1.5 Gy per fraction,3 fraction per week,21 Gy/41/2 wks for 42 patients out of 53 ($76{\%}$). Neutron only but modified fractionation schedule ($10{\%}$ more or less of total dose) was applied for 9 patients, and mixed beam (neutron boost) was for 4 patients, Complete tumor response was obtained in 40 patients ($76{\%}$, response rate). Local control rate was 28 out of 53 ($53{\%}$). Statistically significant better prognostic factors for local control were age below 49 years old (15/22, $68{\%}$) than above 50 years old (13/31, $42{\%}$), male (20/32, $63{\%}$) than female (8/21, $38{\%}$), tumor size less than 5 cm and non-metastatic (16/24, $67{\%}$) than size more than 5 cm or metastatic (12/29, $41{\%}$). Major complication had developed in 7 patients ($13{\%}$). Two year overall survival rate by Kaplan-Meier method was $30{\%}$, but it was rised to, $47{\%}$ when the turner was less than 5 cm non-metastatic.